Neural Stem Cell Based Virotherapy of Newly Diagnosed Malignant Glioma
Neural Stem Cell Oncolytic Adenoviral Virotherapy of Newly Diagnosed Malignant Glioma
Sponsor: National Cancer Institute (NCI)
Listed as NCT03072134, this PHASE1 trial focuses on Anaplastic Astrocytoma and Anaplastic Oligoastrocytoma and remains completed. Sponsored by National Cancer Institute (NCI), it has been updated 11 times since 2017, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Feb 2023 — Jul 2024 [monthly]
Completed PHASE1
-
Feb 2022 — Feb 2023 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Jan 2021 — Feb 2022 [monthly]
Active Not Recruiting PHASE1
▶ Show 6 earlier versions
-
Nov 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE1
Status: Completed → Active Not Recruiting
-
May 2020 — Nov 2020 [monthly]
Completed PHASE1
Status: Recruiting → Completed
-
Sep 2019 — May 2020 [monthly]
Recruiting PHASE1
-
Oct 2018 — Sep 2019 [monthly]
Recruiting PHASE1
-
Jun 2018 — Oct 2018 [monthly]
Recruiting PHASE1
-
May 2017 — Jun 2018 [monthly]
Recruiting PHASE1
First recorded
Apr 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Cancer Institute (NCI)
- Northwestern University
For direct contact, visit the study record on ClinicalTrials.gov .